Aspiriant LLC’s Soleno Therapeutics SLNO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-12,128
| Closed | -$406K | – | 409 |
|
|
2026
Q1 | $406K | Hold |
12,128
| – | – | 0.01% | 245 |
|
|
2025
Q4 | $562K | Hold |
12,128
| – | – | 0.02% | 201 |
|
|
2025
Q3 | $820K | Hold |
12,128
| – | – | 0.03% | 163 |
|
|
2025
Q2 | $1.02M | Hold |
12,128
| – | – | 0.03% | 146 |
|
|
2025
Q1 | $867K | Hold |
12,128
| – | – | 0.03% | 148 |
|
|
2024
Q4 | $545K | Hold |
12,128
| – | – | 0.02% | 184 |
|
|
2024
Q3 | $612K | Hold |
12,128
| – | – | 0.02% | 177 |
|
|
2024
Q2 | $495K | Hold |
12,128
| – | – | 0.02% | 191 |
|
|
2024
Q1 | $519K | Hold |
12,128
| – | – | 0.02% | 196 |
|
|
2023
Q4 | $488K | Buy |
+12,128
| New | +$345K | 0.02% | 192 |
|
|
2022
Q3 | – | Sell |
-3,820
| Closed | -$11K | – | 278 |
|
|
2022
Q2 | $11K | Buy |
3,820
+2,667
| +231% | +$7.38K | ﹤0.01% | 274 |
|
|
2022
Q1 | $4K | Hold |
1,153
| – | – | ﹤0.01% | 274 |
|
|
2021
Q4 | $7K | Hold |
1,153
| – | – | ﹤0.01% | 281 |
|
|
2021
Q3 | $16K | Buy |
+1,153
| New | +$16.1K | ﹤0.01% | 232 |
|
Aspiriant LLC's SLNO Position: Q2 2026 in Review
Aspiriant LLC sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 12,128 shares — an estimated $406K sold.
Aspiriant LLC first reported a position in SLNO in Q3 2021 and held it in 14 quarters. The position peaked at $1.02M in Q2 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.
- Aspiriant LLC reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
- Aspiriant LLC sold 12,128 Soleno Therapeutics shares in Q2 2026, an estimated $406K.
- Aspiriant LLC first reported a position in Soleno Therapeutics in Q3 2021 and held it in 14 quarters.
- Aspiriant LLC's Soleno Therapeutics position peaked at $1.02M in Q2 2025.
- 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.
Based on Aspiriant LLC's 13F filing for Q2 2026, filed 20 Jul 2026.